Metropolitan Life Insurance CO Next Cure, Inc. Transaction History

Metropolitan Life Insurance CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$8.15 - $21.17 $41,687 - $108,284	-5,115 Closed	0 $0
Q2 2020 Jun 26, 2023	BUY	$21.19 - $40.2 $108,386 - $205,623	5,115 New	5,115 $109,000
Q2 2020 Mar 30, 2023	BUY	$21.19 - $40.2 $11,273 - $21,386	532 Added 11.61%	5,115 $109,000
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $11,273 - $21,386	532 Added 11.61%	5,115 $110,000
Q1 2020 Jul 12, 2023	BUY	$32.32 - $58.37 $148,122 - $267,509	4,583 New	4,583 $169,000

Q4 2019 Jul 12, 2023	BUY	$25.0 - $92.22 $114,575 - $422,644	4,583 New	4,583 $258,000
Q4 2019 Mar 30, 2023	BUY	$25.0 - $92.22 $114,575 - $422,644	4,583 New	4,583 $258,000
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $114,575 - $422,644	4,583 New	4,583 $258,000

783K

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $263M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.